| Reference | </br>1:Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients. Domínguez-Hermosillo JC, Mata-Marin JA, Herrera-González NE, Chávez-García M, Huerta-García G, Nuñez-Rodríguez N, García-Gámez JG, Jiménez-Romero A, Gaytán-Martínez JE.J Infect Dev Ctries. 2016 Sep 30;10(9):982-987. doi: 10.3855/jidc.6629. PMID: 27694731 Free Article</br>2:Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team..PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016. PMID: 26730818 Free PMC Article</br>3:Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D, Wajima T, Savina P, Peppercorn A, Castellino S, Wagner D, Hosking L, Mosteller M, Rubio JP, Piscitelli SC.Eur J Clin Pharmacol. 2014 Oct;70(10):1173-9. doi: 10.1007/s00228-014-1732-8. Epub 2014 Aug 23. PMID: 25146692 Free PMC Article</br>4:Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience. Salazar JC, Cahn P, Della Negra M, De Aquino MZ, Robinson PA, Jelaska A, Mikl J.Pediatr Infect Dis J. 2014 Apr;33(4):396-400. doi: 10.1097/INF.0000000000000038. PMID: 23995585 </br>5:Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials. Berhan A, Berhan Y.PLoS One. 2013 Apr 4;8(4):e60814. doi: 10.1371/journal.pone.0060814. Print 2013. PMID: 23593314 Free PMC Article</br>6:Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. Aoki M, Danish ML, Aoki-Ogata H, Amano M, Ide K, Das D, Koh Y, Mitsuya H.J Virol. 2012 Dec;86(24):13384-96. doi: 10.1128/JVI.07234-11. Epub 2012 Sep 26. PMID: 23015723 Free PMC Article</br>7:Tipranavir in the protease inhibitors arena. Vergani B, Rusconi S.Drugs R D. 2011 Dec 1;11(4):291-3. doi: 10.2165/11594570-000000000-00000. Review. No abstract available. PMID: 22133386 Free PMC Article</br>8:Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes. Bethell R, Scherer J, Witvrouw M, Paquet A, Coakley E, Hall D.AIDS Res Hum Retroviruses. 2012 Sep;28(9):1019-24. doi: 10.1089/AID.2011.0242. Epub 2012 Mar 23. PMID: 22098079 </br>9:Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan. Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.Int J STD AIDS. 2011 Nov;22(11):617-20. doi: 10.1258/ijsa.2009.009007. PMID: 22096044 </br>10:Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial. Elgadi MM, Piliero PJ.Drugs R D. 2011 Dec 1;11(4):295-302. doi: 10.2165/11596340-000000000-00000. PMID: 22007990 Free PMC Article
|
